Diametric Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Diametric Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42,945	Closed	-$150K	–	506
2025 Q3	$150K	Buy	+42,945	New	+$147K	0.06%	354
2024 Q2	–	Sell	-22,201	Closed	-$35.1K	–	469
2024 Q1	$35.1K	Sell	22,201 -35,894	-62%	-$68.2K	0.02%	309
2023 Q4	$119K	Sell	58,095 -97,249	-63%	-$169K	0.07%	222
2023 Q3	$217K	Buy	155,344 +26,952	+21%	+$27.9K	0.09%	264
2023 Q2	$70.6K	Buy	+128,392	New	+$67.9K	0.03%	298

Other funds holding STLN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diametric Capital's STLN Position: Q4 2025 in Review

Diametric Capital sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2025, closing a stake of 42,945 shares — an estimated $150K sold.

Diametric Capital first reported a position in STLN in Q2 2023 and held it in 5 quarters. The position peaked at $217K in Q3 2023. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

Diametric Capital reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
Diametric Capital sold 42,945 Starling Oncology Institute, Inc. Common Stock shares in Q4 2025, an estimated $150K.
Diametric Capital first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2023 and held it in 5 quarters.
Diametric Capital's Starling Oncology Institute, Inc. Common Stock position peaked at $217K in Q3 2023.
117 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2025.

Based on Diametric Capital's 13F filing for Q4 2025, filed 13 Feb 2026.